- INICIO
-
Genéricos
Novedades
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
Investigación
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
- Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
- Trajectories of prices in generic drug markets
-
Biosimilares
Novedades
- FDA approves first natalizumab biosimilar Tyruko for MS
- EMA recommends approval of first natalizumab biosimilar Tyruko for MS
- EMA recommends approval of first aflibercept and tocilizumab biosimilars
- Alvotech: rejection AVT02 in the US and new partnerships with Prolifarma and Advanz Pharma
Investigación
- Biosimilares oftalmológicos en Canadá: la perspectiva de un prescriptor
- Respuesta a Opinión sobre: Cuatro pasos para racionalizar el desarrollo de biosimilares
- Cuatro pasos para racionalizar el desarrollo de biosimilares
- Biosimilares: actitudes y percepciones de los prescriptores estadounidenses
General
- Coherus retracts AbbVie restraining order in Humira biosimilar dispute
- Proposal to widen access to trastuzumab in New Zealand
- Actualización de la declaración de posición de GADECCU sobre los biosimilares
- GADECCU presenta un nuevo posicionamiento sobre biosimilares
- MORE EDITORIAL SECTIONS
- Search
